Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Robert J, Gray"'
Autor:
James K. Ruffle, Robert J Gray, Samia Mohinta, Guilherme Pombo, Chaitanya Kaul, Harpreet Hyare, Geraint Rees, Parashkev Nachev
Publikováno v:
NeuroImage, Vol 291, Iss , Pp 120600- (2024)
Our knowledge of the organisation of the human brain at the population-level is yet to translate into power to predict functional differences at the individual-level, limiting clinical applications and casting doubt on the generalisability of inferre
Externí odkaz:
https://doaj.org/article/bffad76a626b4c6897c835435a69cb38
Autor:
Amy P.K. Nelson, Robert J. Gray, James K. Ruffle, Henry C. Watkins, Daniel Herron, Nick Sorros, Danil Mikhailov, M. Jorge Cardoso, Sebastien Ourselin, Nick McNally, Bryan Williams, Geraint E. Rees, Parashkev Nachev
Publikováno v:
Patterns, Vol 3, Iss 5, Pp 100483- (2022)
Summary: The value of biomedical research—a $1.7 trillion annual investment—is ultimately determined by its downstream, real-world impact, whose predictability from simple citation metrics remains unquantified. Here we sought to determine the com
Externí odkaz:
https://doaj.org/article/f9484feb9cbb4f8aa7b49a16d34fe9b0
Autor:
Joseph M. Unger, Michael LeBlanc, Suzanne George, Norman Wolmark, Walter J. Curran, Peter J. O'Dwyer, Mitchell D. Schnall, Robert S. Mannel, Sumithra J. Mandrekar, Robert J. Gray, Fengmin Zhao, Mariama Bah, Riha Vaidya, Charles D. Blanke
Publikováno v:
Journal of Clinical Oncology. 41:2020-2028
PURPOSE In the United States, the National Cancer Institute National Cancer Clinical Trials Network (NCTN) groups have conducted publicly funded oncology research for 50 years. The combined impact of all adult network group trials has never been syst
Autor:
Joseph Sparano, Robert J. Gray, Della Makower, Kathy S. Albain, Daniel F. Hayes, Charles Geyer, Elizabeth Dees, Matthew P. Goetz, John A. Olson, Tracy G. Lively, Sunil Badve, Thomas Saphner, Lynne I. Wagner, Timothy Whelan, Virginia Kaklamani, George Sledge
Publikováno v:
Cancer Research. 83:GS1-05
Background: Late recurrence of breast cancer after 5 years accounts for about 50% of recurrences in hormone receptor (HR)-positive early breast cancer (EBC). TAILORx established non-inferiority of adjuvant endocrine therapy (ET) given for at least 5
Autor:
Amy S. Clark, Fangxin Hong, Richard S. Finn, Angela M. DeMichele, Edith P. Mitchell, James Zwiebel, Fernanda I. Arnaldez, Robert J. Gray, Victoria Wang, Lisa M. McShane, Larry V. Rubinstein, David Patton, P. Mickey Williams, Stanley R. Hamilton, Mehmet S. Copur, Samer S. Kasbari, Ravneet Thind, Barbara A. Conley, Carlos L. Arteaga, Peter J. O'Dwyer, Lyndsay N. Harris, Alice P. Chen, Keith T. Flaherty
Publikováno v:
Clinical Cancer Research. 29:1477-1483
Purpose: Cyclin D/CDK4/6 is critical in controlling the G1 to S checkpoint. CCND, the gene encoding cyclin D, is known to be amplified in a variety of solid tumors. Palbociclib is an oral CDK4/6 inhibitor, approved in advanced breast cancer in combin
Autor:
Funda Meric-Bernstam, James M. Ford, Peter J. O'Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin, Roisin E. O'Cearbhaill, Suzanne George, Julia Glade-Bender, Gary H. Lyman, James V. Tricoli, David Patton, Stanley R. Hamilton, Robert J. Gray, Douglas S. Hawkins, Bhanumati Ramineni, Keith T. Flaherty, Petros Grivas, Timothy A. Yap, Jordan Berlin, James H. Doroshow, Lyndsay N. Harris, Jeffrey A. Moscow
Publikováno v:
Clinical Cancer Research. 29:1412-1422
Over the past decade, multiple trials, including the precision medicine trial National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH, EAY131, NCT02465060) have sought to determine if treating cancer based on specific genomic alter
Autor:
Philippe L. Bedard, Shuli Li, Kari B. Wisinski, Eddy S. Yang, Sewanti A. Limaye, Edith P. Mitchell, James A. Zwiebel, Jeffrey A. Moscow, Robert J. Gray, Victoria Wang, Lisa M. McShane, Larry V. Rubinstein, David R. Patton, P. Mickey Williams, Stanley R. Hamilton, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O'Dwyer, Alice P. Chen, Keith T. Flaherty
Publikováno v:
JCO precision oncology. 6
PURPOSE National Cancer Institute–Molecular Analysis for Therapy Choice is a multicohort trial that assigns patients with advanced cancers to targeted therapies on the basis of central tumor genomic testing. Arm B evaluated afatinib, an ErbB family
Autor:
Senthil, Damodaran, Fengmin, Zhao, Dustin A, Deming, Edith P, Mitchell, John J, Wright, Robert J, Gray, Victoria, Wang, Lisa M, McShane, Larry V, Rubinstein, David R, Patton, P Mickey, Williams, Stanley R, Hamilton, Jennifer M, Suga, Barbara A, Conley, Carlos L, Arteaga, Lyndsay N, Harris, Peter J, O'Dwyer, Alice P, Chen, Keith T, Flaherty
Publikováno v:
J Clin Oncol
Activating mutations in PIK3CA are observed across multiple tumor types. The NCI-MATCH (EAY131) is a tumor-agnostic platform trial that enrolls patients to targeted therapies on the basis of matching genomic alterations. Arm Z1F evaluated copanlisib,
Autor:
Jeffrey A. Moscow, Lyndsay N. Harris, James H. Doroshow, Jordan Berlin, Timothy A. Yap, Petros Grivas, Keith T. Flaherty, Bhanumati Ramineni, Douglas S. Hawkins, Robert J. Gray, Stanley R. Hamilton, David Patton, James V. Tricoli, Gary H. Lyman, Julia Glade-Bender, Suzanne George, Roisin E. O'Cearbhaill, Boris Freidlin, Lisa M. McShane, Geoffrey I. Shapiro, Peter J. O'Dwyer, James M. Ford, Funda Meric-Bernstam
supplementary table TS1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11429ff581ea4e4e6669e078777ce535
https://doi.org/10.1158/1078-0432.22633057.v1
https://doi.org/10.1158/1078-0432.22633057.v1
Autor:
Jeffrey A. Moscow, Lyndsay N. Harris, James H. Doroshow, Jordan Berlin, Timothy A. Yap, Petros Grivas, Keith T. Flaherty, Bhanumati Ramineni, Douglas S. Hawkins, Robert J. Gray, Stanley R. Hamilton, David Patton, James V. Tricoli, Gary H. Lyman, Julia Glade-Bender, Suzanne George, Roisin E. O'Cearbhaill, Boris Freidlin, Lisa M. McShane, Geoffrey I. Shapiro, Peter J. O'Dwyer, James M. Ford, Funda Meric-Bernstam
Over the past decade, multiple trials, including the precision medicine trial National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH, EAY131, NCT02465060) have sought to determine if treating cancer based on specific genomic alter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d95ce7ea2922f53625334065386b4e22
https://doi.org/10.1158/1078-0432.c.6533210
https://doi.org/10.1158/1078-0432.c.6533210